Table 2.
Baseline characteristics of patients enrolled in the CARE-MS-1 and CARE-MS-2 trials
| CARE-MS-1 (alemtuzumab as first-line treatment)16
|
CARE-MS-2 (alemtuzumab after failure of disease-modifying therapy)17,a
|
|||
|---|---|---|---|---|
| IFN beta-1a (n=187) | Alemtuzumab 12 mg (n=376) | IFN beta-1a (n=202) | Alemtuzumab 12 mg (n=426) | |
| Age, years | 33.2±8.5 | 33.0±8.0 | 35.8±8.8 | 34.8±8.4 |
| Sex, female | 122 (65%) | 243 (65%) | 131 (65%) | 281 (66%) |
| Mean EDSS | 2.0±0.8 | 2.0±0.8 | 2.7±1.2 | 2.7±1.3 |
| Mean disease duration | 2.0±1.3 | 2.1±1.4 | 4.7±2.9 | 4.5±2.7 |
| Mean number of relapses in previous year | 1.8±0.8 | 1.8±0.8 | 1.5±0.8 | 1.7±0.9 |
| Mean number of Gd-enhancing T1-weighted lesions | 2.2±4.9 | 2.3±5.1 | 2.1±5.0 | 2.3±6.0 |
| Mean number of T2-hyperintense lesions | 7.3±9.9 | 7.4±9.0 | 9.0±10.4 | 9.9±12.3 |
Notes: Data presented as mean ± standard deviation unless otherwise stated;
a
Alemtuzumab 24 mg arm not shown, as not included in primary efficacy analysis. Data from Cohen et al16 and Coles et al.17
Abbreviations: EDSS, expanded disability status scale; Gd, gadolinium; IFN, interferon; CARE-MS, Comparison of Alemtuzumab and Rebif® efficacy in Multiple Sclerosis.